NO20021567L - Stabiliserte flytende polypeptidinneholdende farmasöytiske sammensetninger - Google Patents

Stabiliserte flytende polypeptidinneholdende farmasöytiske sammensetninger

Info

Publication number: NO20021567L
Authority: NO; Norway
Prior art keywords: acid; polypeptide; amino acid; arginine; variants
Prior art date: 1999-10-04

Application number

NO20021567A

Other languages

English (en)

Other versions

NO20021567D0 (no

Inventor

Bao-Lu Chen

Maninder Hora

Original Assignee

Chiron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-04

Filing date

2002-04-03

Publication date

2002-05-22

2002-04-03 Application filed by Chiron Corp filed Critical Chiron Corp

2002-04-03 Publication of NO20021567D0 publication Critical patent/NO20021567D0/no

2002-05-22 Publication of NO20021567L publication Critical patent/NO20021567L/no

Links

239000007788 liquid Substances 0.000 title abstract 7
239000008194 pharmaceutical composition Substances 0.000 title abstract 7
229920001184 polypeptide Polymers 0.000 title abstract 7
102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
150000003839 salts Chemical group 0.000 abstract 8
235000001014 amino acid Nutrition 0.000 abstract 7
150000001413 amino acids Chemical class 0.000 abstract 7
239000004475 Arginine Substances 0.000 abstract 6
235000009697 arginine Nutrition 0.000 abstract 6
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 6
239000002253 acid Substances 0.000 abstract 5
239000002585 base Substances 0.000 abstract 5
102100030951 Tissue factor pathway inhibitor Human genes 0.000 abstract 4
230000015572 biosynthetic process Effects 0.000 abstract 4
108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 abstract 4
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 4
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 3
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 3
239000004472 Lysine Substances 0.000 abstract 3
150000007513 acids Chemical class 0.000 abstract 3
235000003704 aspartic acid Nutrition 0.000 abstract 3
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
239000012458 free base Substances 0.000 abstract 3
235000013922 glutamic acid Nutrition 0.000 abstract 3
239000004220 glutamic acid Substances 0.000 abstract 3
235000018977 lysine Nutrition 0.000 abstract 3
239000000203 mixture Substances 0.000 abstract 3
102000000588 Interleukin-2 Human genes 0.000 abstract 2
108010002350 Interleukin-2 Proteins 0.000 abstract 2
239000006172 buffering agent Substances 0.000 abstract 2
239000012669 liquid formulation Substances 0.000 abstract 2
239000001384 succinic acid Substances 0.000 abstract 2
239000013543 active substance Substances 0.000 abstract 1
239000000872 buffer Substances 0.000 abstract 1
230000001747 exhibiting effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Rheumatology (AREA)
Psychology (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Transplantation (AREA)
Diabetes (AREA)

NO20021567A 1999-10-04 2002-04-03 Stabiliserte flytende polypeptidinneholdende farmasöytiske sammensetninger NO20021567L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15769699P	1999-10-04	1999-10-04
PCT/US2000/027156 WO2001024814A1 (en)	1999-10-04	2000-10-03	Stabilized liquid polypeptide-containing pharmaceutical compositions

Publications (2)

Publication Number	Publication Date
NO20021567D0 NO20021567D0 (no)	2002-04-03
NO20021567L true NO20021567L (no)	2002-05-22

Family

ID=22564882

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20021567A NO20021567L (no)	1999-10-04	2002-04-03	Stabiliserte flytende polypeptidinneholdende farmasöytiske sammensetninger
NO20044406A NO20044406L (no)	1999-10-04	2004-10-15	Stabilisert flytende farmasoytisk sammensetning samt fremgangsmate for a oke stabiliteten av IL-2

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20044406A NO20044406L (no)	1999-10-04	2004-10-15	Stabilisert flytende farmasoytisk sammensetning samt fremgangsmate for a oke stabiliteten av IL-2

Country Status (18)

Country	Link
US (4)	US6525102B1 (no)
EP (2)	EP1491208B1 (no)
JP (2)	JP2003510368A (no)
CN (2)	CN1245216C (no)
AT (2)	ATE345810T1 (no)
AU (2)	AU783306B2 (no)
BR (2)	BR0014486A (no)
CA (2)	CA2386228A1 (no)
CZ (2)	CZ305123B6 (no)
DE (2)	DE60044213D1 (no)
ES (1)	ES2276698T3 (no)
HU (3)	HU0800692D0 (no)
IL (3)	IL149008A0 (no)
NO (2)	NO20021567L (no)
NZ (2)	NZ529856A (no)
PL (2)	PL211886B1 (no)
PT (1)	PT1491208E (no)
WO (1)	WO2001024814A1 (no)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7006874B2 (en) *	1996-01-05	2006-02-28	Thermage, Inc.	Treatment apparatus with electromagnetic energy delivery device and non-volatile memory
JP2000247903A (ja) *	1999-03-01	2000-09-12	Chugai Pharmaceut Co Ltd	長期安定化製剤
CN1245216C (zh) *	1999-10-04	2006-03-15	希龙公司	稳定化的含多肽的液体药物组合物
SK11142002A3 (sk) *	1999-12-30	2004-09-08	Chiron Corporation	Liečivo na podávanie interleukínu-2 a stabilizovaný lyofilizovaný alebo sprejovo sušený farmaceutický prostriedok s obsahom interleukínu-2
US6495534B2 (en) *	2000-05-15	2002-12-17	Pharmacia & Upjohn Spa	Stabilized aqueous suspensions for parenteral use
EP1935431A3 (en)	2000-05-15	2008-08-13	Health Research, Inc.	Cancer treatments by using a combination of an antibody against her2 and interleukin-2
JP4147234B2 (ja)	2004-09-27	2008-09-10	キヤノン株式会社	吐出用液体、吐出方法、カートリッジ及び吐出装置
EP2116265B1 (en)	2000-10-12	2020-12-23	Genentech, Inc.	Reduced-viscosity concentrated protein formulations
US8703126B2 (en)	2000-10-12	2014-04-22	Genentech, Inc.	Reduced-viscosity concentrated protein formulations
CA2441192C (en) *	2001-03-23	2009-05-19	Ajinomoto Co., Inc.	The use of lysine for the prevention or treatment of stress-induced diseases
US6887462B2 (en) *	2001-04-09	2005-05-03	Chiron Corporation	HSA-free formulations of interferon-beta
DE10149030A1 (de) *	2001-10-05	2003-04-10	Viscum Ag	Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
KR20050036867A (ko)	2001-10-15	2005-04-20	카이론 코포레이션	조직인자경로 억제제（ｔｆｐｉ）의 투여에 의한 중증폐렴의 치료
PT1450847E (pt)	2001-11-13	2011-01-05	Genentech Inc	Formulações de ligando de apo2/trail e suas utilizações
US7842668B1 (en)	2001-11-13	2010-11-30	Genentech, Inc.	Apo-2 ligand/trail formulations
EP3210624A1 (en) *	2002-02-27	2017-08-30	Immunex Corporation	Stabilized tnfr-fc composition comprising arginine
WO2003072060A2 (en)	2002-02-27	2003-09-04	Immunex Corporation	Polypeptide formulation
US6991805B1 (en) *	2002-09-06	2006-01-31	Health Research, Inc.	Temperature sensitive control of liposome-cell adhesion
US6964778B1 (en) *	2002-09-06	2005-11-15	Health Research, Inc.	Temperature controlled content release from liposomes
AU2003268664A1 (en) *	2002-09-26	2004-04-19	Shionogi And Co., Ltd.	Stabilized protein compositions
DE602004015725D1 (de) *	2003-01-08	2008-09-25	Novartis Vaccines & Diagnostic	Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
EP1803445A3 (en) *	2003-01-08	2007-11-21	Novartis Vaccines and Diagnostics, Inc.	Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
EA008038B1 (ru)	2003-01-08	2007-02-27	Чирон Корпорейшн	Стабилизированные водные композиции, содержащие ингибитор пути метаболизма, тканевого фактора (tfpi) или вариант ингибитора пути метаболизма тканевого фактора
US20040208869A1 (en) *	2003-01-30	2004-10-21	Medimmune, Inc.	Uses of anti-integrin alphanubeta3 antibody formulations
US20040208870A1 (en) *	2003-01-30	2004-10-21	Medimmune, Inc.	Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
ATE404175T1 (de) *	2003-03-31	2008-08-15	Alza Corp	Nicht wässrige einphasige visköse vehikel und formulierungen die diese vehikel verwenden
WO2004091658A1 (en)	2003-04-04	2004-10-28	Genentech, Inc.	High concentration antibody and protein formulations
US7291501B2 (en) *	2003-07-16	2007-11-06	Abbott Laboratories	Stable compositions for measuring human natriuretic peptides
US7445933B2 (en) *	2003-07-16	2008-11-04	Abbott Laboratories, Inc.	Stable calibrators or controls for measuring human natriuretic peptides
ATE516306T1 (de) *	2003-08-13	2011-07-15	Novartis Vaccines & Diagnostic	Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen
US7141544B2 (en)	2003-10-10	2006-11-28	Baxter International, Inc.	Stabilization of pharmaceutical protein formulations with small peptides
DE10348550A1 (de) *	2003-10-20	2005-06-16	Hexal Biotech Forschungsgmbh	Stabile wässrige G-CSF-haltige Zusammensetzungen
DE602004028037D1 (de)	2003-11-04	2010-08-19	Novartis Vaccines & Diagnostic	Verfahren zur behandlung von krebs mit expression des cd40-antigens
US20050136542A1 (en) *	2003-12-19	2005-06-23	Beckman Coulter, Inc.	Stabilized liquid reference solutions
JP4845741B2 (ja) *	2003-12-23	2011-12-28	ファルマシアコーポレーション	安定な成長ホルモン液体製剤
JPWO2005063291A1 (ja) *	2003-12-25	2007-07-19	麒麟麦酒株式会社	抗体を含有する安定な水性医薬製剤
CA2552758A1 (en) *	2004-01-13	2005-08-04	Vasogenix Pharmaceuticals, Inc.	Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same
JP2007517911A (ja) *	2004-01-13	2007-07-05	バソジェニックスファーマシューティカルズ，インコーポレイテッド	心臓血管の適応症および腎臓の適応症に対してｃｇｒｐを使用する方法
CA2552677A1 (en) *	2004-01-13	2005-07-28	Vasogenix Pharmaceuticals, Inc.	Controlled release cgrp delivery composition for cardiovascular and renal indications
CA2560103A1 (en) *	2004-03-17	2005-11-24	Chiron Corporation	Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
PL1729810T3 (pl) *	2004-04-02	2019-02-28	Swedish Orphan Biovitrum Ab (Publ)	Sposoby agregacji IL-1ra
BRPI0510526A (pt) *	2004-06-01	2007-10-30	Ares Trading Sa	formulações lìquidas estabilizadas de interferon
DE102004059776A1 (de) *	2004-09-17	2006-04-06	Deutsches Zentrum für Luft- und Raumfahrt e.V.	Brennstoffzellensystem
JP4147235B2 (ja)	2004-09-27	2008-09-10	キヤノン株式会社	吐出用液体、吐出方法、液滴化方法、液体吐出カートリッジ及び吐出装置
NZ584597A (en) *	2004-12-22	2011-09-30	Ambrx Inc	Modified human growth hormone
CN101106979A (zh) *	2005-01-21	2008-01-16	阿尔扎公司	具有改善的稳定性的含有至少一种反离子的用于涂覆微针的治疗性的肽试剂
CN100336557C (zh) *	2005-05-11	2007-09-12	北京双鹭药业股份有限公司	一种生长抑素的水溶液制剂、其制备方法及应用
CN100337684C (zh) *	2005-05-11	2007-09-19	北京双鹭药业股份有限公司	一种胸腺五肽的水溶液制剂、其制备方法及应用
CN100342909C (zh) *	2005-05-11	2007-10-17	北京双鹭药业股份有限公司	一种胸腺素α1的水溶液制剂、其制备方法及应用
AU2006247188A1 (en)	2005-05-18	2006-11-23	Children's Hospital & Research Center At Oakland	Methods and compositions for immunizing against chlamydia infection
KR100769709B1 (ko) *	2005-05-31	2007-10-23	주식회사 대웅	인성장호르몬을 함유하는 안정한 액상 제제
MX2007015476A (es)	2005-06-14	2008-02-25	Amgen Inc	Formulaciones de proteina autoamortiguadoras.
US20070027105A1 (en)	2005-07-26	2007-02-01	Alza Corporation	Peroxide removal from drug delivery vehicle
US8168592B2 (en) *	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
US20070191271A1 (en) *	2006-02-10	2007-08-16	Dow Pharmaceutical Sciences	Method for stabilizing polypeptides lacking methionine
WO2007103425A2 (en) *	2006-03-06	2007-09-13	Novartis Ag	Kits and methods for preparing pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi)
TW200806317A (en) *	2006-03-20	2008-02-01	Wyeth Corp	Methods for reducing protein aggregation
SMP200800064B (it)	2006-04-21	2009-11-06	Novartis Ag	Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
ES2605022T3 (es) *	2006-07-06	2017-03-10	Daewoong Co., Ltd.	Una formulación líquida estable de la hormona del crecimiento humana
CN105412910A (zh) *	2006-07-06	2016-03-23	株式会社大熊	稳定的人生长激素液体制剂
US7923425B2 (en) *	2006-08-21	2011-04-12	Henkel Ag & Co. Kgaa	Low-foaming, acidic low-temperature cleaner and process for cleaning surfaces
US7767206B2 (en)	2006-10-02	2010-08-03	Amgen Inc.	Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
MX2009013886A (es) *	2007-06-25	2010-01-27	Amgen Inc	Composiciones de agentes de aglutinacion especifica al factor de crecimiento de los hepatocitos.
JP2010532790A (ja) *	2007-07-06	2010-10-14	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	抗体処方
UA107557C2 (xx) *	2007-07-06	2015-01-26		Композиція антитіла офатумумабу
PE20091174A1 (es)	2007-12-27	2009-08-03	Chugai Pharmaceutical Co Ltd	Formulacion liquida con contenido de alta concentracion de anticuerpo
PL2229407T3 (pl)	2008-01-09	2017-06-30	Sanofi-Aventis Deutschland Gmbh	Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
BRPI0907077A2 (pt)	2008-03-26	2016-07-26	Oramed Ltd	métodos e composições para administração oral de proteínas
KR101820024B1 (ko)	2008-10-17	2018-01-18	사노피-아벤티스 도이칠란트 게엠베하	인슐린과 ｇｌｐ－1 효능제의 병용물
KR20110086705A (ko) *	2008-11-17	2011-07-29	제넨테크, 인크.	생리학적 조건 하에 거대분자의 응집을 감소시키는 방법 및 제제
TW201039854A (en)	2009-03-06	2010-11-16	Genentech Inc	Antibody formulation
SG10201403840VA (en) *	2009-07-06	2014-10-30	Sanofi Aventis Deutschland	Aqueous insulin preparations containing methionine
CN105126086B (zh)	2009-07-28	2019-05-14	夏尔人类遗传性治疗公司	用于治疗戈谢病的组合物和方法
WO2011017070A1 (en) *	2009-07-28	2011-02-10	Merck Sharp & Dohme Corp.	Methods for producing high concentration lyophilized pharmaceutical formulations
TR201809460T4 (tr)	2009-11-13	2018-07-23	Sanofi Aventis Deutschland	Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
EP3345593B1 (de)	2009-11-13	2023-09-06	Sanofi-Aventis Deutschland GmbH	Pharmazeutische zusammensetzung umfassend despro36exendin-4(1-39)-lys6-nh2 und methionin
CA2780554C (en) *	2009-11-17	2017-08-15	Ipsen Pharma S.A.S.	Formulation for hgh and rhigf-1 combination
JP5743234B2 (ja)	2010-01-15	2015-07-01	キリン−アムジェン・インコーポレーテッド	抗体製剤及び治療レジメン
SI3409289T1 (sl)	2010-02-26	2020-12-31	Novo Nordisk A/S	Stabilni sestavki, ki vsebujejo protitelo
RS56409B1 (sr)	2010-03-01	2018-01-31	Bayer Healthcare Llc	Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
US20130136733A1 (en)	2010-05-28	2013-05-30	Novo Nordisk A/S	Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
ES2606554T3 (es)	2010-08-30	2017-03-24	Sanofi-Aventis Deutschland Gmbh	Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
BR112013006088B1 (pt)	2010-09-15	2022-06-14	Randall J Mrsny	Construto de entrega isolado, e, composição farmacêutica
US11246915B2 (en)	2010-09-15	2022-02-15	Applied Molecular Transport Inc.	Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2726495B1 (en) *	2011-06-28	2019-03-06	Leukocare Ag	Method for preventing the unfolding of a (poly)peptide and/or inducing the (re-)folding of a (poly)peptide
TWI608847B (zh)	2011-08-29	2017-12-21	賽諾菲阿凡提斯德意志有限公司	用於控制糖尿病二型病患血糖的醫藥組合物
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
AU2012328524B2 (en)	2011-10-28	2017-05-18	Excelse Bio, Inc.	Protein formulations containing amino acids
US8613919B1 (en)	2012-08-31	2013-12-24	Bayer Healthcare, Llc	High concentration antibody and protein formulations
US8883979B2 (en)	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
JP6171331B2 (ja) *	2012-12-25	2017-08-02	東ソー株式会社	Ｆｃ結合性タンパク質の精製方法および定量方法
JP2016505613A (ja) *	2013-01-03	2016-02-25	オラムドエルティーディー．	Ｎａｆｌｄ、脂肪肝、および、その後遺症を処置するための方法および組成物
TWI641381B (zh)	2013-02-04	2018-11-21	法商賽諾菲公司	胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
HUE049707T2 (hu) *	2013-03-13	2020-11-30	Hoffmann La Roche	Csökkent oxidációjú kiszerelések
US20140314778A1 (en)	2013-03-13	2014-10-23	Genentech, Inc.	Formulations with reduced oxidation
US10653779B2 (en)	2013-03-13	2020-05-19	Genentech, Inc.	Formulations with reduced oxidation
AR095348A1 (es)	2013-03-15	2015-10-07	Genentech Inc	Medios de cultivo celular y métodos de producción de anticuerpos
CA2923859C (en)	2013-09-11	2021-11-23	Arsia Therapeutics, Inc.	Liquid protein formulations containing viscosity-lowering agents
JP2014062100A (ja) *	2013-11-05	2014-04-10	Glaxosmithkline Llc	抗体処方
WO2015104314A1 (en)	2014-01-09	2015-07-16	Sanofi	Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604708VA (en)	2014-01-09	2016-07-28	Sanofi Sa	Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
KR20160101195A (ko)	2014-01-09	2016-08-24	사노피	인슐린 아스파트의 안정화된 약제학적 제형
US10260111B1 (en)	2014-01-20	2019-04-16	Brett Eric Etchebarne	Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
EP3998077A1 (en)	2014-05-07	2022-05-18	Applied Molecular Transport Inc.	Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US10478498B2 (en)	2014-06-20	2019-11-19	Reform Biologics, Llc	Excipient compounds for biopolymer formulations
US11357857B2 (en)	2014-06-20	2022-06-14	Comera Life Sciences, Inc.	Excipient compounds for protein processing
WO2015196091A1 (en)	2014-06-20	2015-12-23	Reform Biologics, Llc	Viscosity-reducing excipient compounds for protein formulations
US11471479B2 (en)	2014-10-01	2022-10-18	Eagle Biologics, Inc.	Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
PE20171622A1 (es)	2014-12-12	2017-11-02	Sanofi Aventis Deutschland	Formulacion de relacion fija de insulina glargina/lixisenatida
AR103173A1 (es) *	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
JP6247241B2 (ja) *	2015-02-27	2017-12-13	ノバルティスアーゲー	抗体処方
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
US10576129B2 (en) *	2015-04-21	2020-03-03	Staidson (Beijing) Biopharmaceuticals Co., Ltd.	Nerve growth factor composition and powder injection
JP7008023B2 (ja)	2015-12-30	2022-01-25	ジェネンテック，インコーポレイテッド	低減されたポリソルベート分解を有する製剤
WO2018038301A1 (en) *	2016-08-26	2018-03-01	Hugel Inc.	Stabilized liquid formulation of botulinum toxin and preparation method thereof
CN114917185B (zh)	2016-10-21	2023-11-14	美国安进公司	药物配制品及其制备方法
CA3056630A1 (en)	2017-03-15	2018-09-20	Pandion Therapeutics, Inc.	Targeted immunotolerance
KR20200010354A (ko)	2017-05-24	2020-01-30	팬디온 테라퓨틱스, 인코포레이티드	표적화된 면역관용
JP6901801B2 (ja) *	2017-06-14	2021-07-14	バイオソリューションカンパニー・リミテッドＢｉｏＳｏｌｕｔｉｏｎＣｏＬｔｄ	物質ｐを含むしわの改善または抗炎症化粧料組成物
EP3664893A1 (en) *	2017-08-08	2020-06-17	CSL Behring AG	Hemopexin formulations
US10946068B2 (en)	2017-12-06	2021-03-16	Pandion Operations, Inc.	IL-2 muteins and uses thereof
US10174091B1 (en)	2017-12-06	2019-01-08	Pandion Therapeutics, Inc.	IL-2 muteins
EP3762009B1 (en)	2018-03-08	2022-05-11	Applied Molecular Transport Inc.	Toxin-derived delivery constructs for oral delivery
AU2019230230A1 (en)	2018-03-08	2020-10-22	Applied Molecular Transport Inc.	Toxin-derived delivery constructs for oral delivery
JP2021528101A (ja) *	2018-06-13	2021-10-21	アクロンバイオテクノロジー，エルエルシー．	液体医薬組成物中で非常に安定な治療的に活性なアルデスロイキンを調製する方法
WO2020236875A1 (en)	2019-05-20	2020-11-26	Pandion Therapeutics, Inc.	Madcam targeted immunotolerance
CN114599665A (zh)	2019-08-16	2022-06-07	应用分子转运公司	组合物、制剂及白细胞介素产生和纯化
BR112022013730A2 (pt) *	2020-01-13	2022-10-11	Aptevo Res & Development Llc	Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
KR20220140711A (ko)	2020-01-13	2022-10-18	듀렉트 코퍼레이션	불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
US11981715B2 (en)	2020-02-21	2024-05-14	Pandion Operations, Inc.	Tissue targeted immunotolerance with a CD39 effector
CN115427437B (zh) *	2020-03-31	2024-04-19	韩美药品株式会社	新型免疫刺激il-2类似物
AU2022232401A1 (en) *	2021-03-11	2023-09-21	89Bio, Inc.	Liquid formulations comprising mutant fgf-21 peptide pegylated conjugates
CN117120070A (zh) *	2021-03-11	2023-11-24	89生物公司	包含突变型fgf-21肽peg化缀合物的液体制剂
CN117883376B (zh) *	2024-03-14	2024-06-25	北京四环生物制药有限公司	含重组人白细胞介素-2的药物制剂及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4966843A (en)	1982-11-01	1990-10-30	Cetus Corporation	Expression of interferon genes in Chinese hamster ovary cells
EP0158487B1 (en)	1984-04-09	1991-08-28	Takeda Chemical Industries, Ltd.	Stable composition of interleukin-2
JPS60215631A (ja) *	1984-04-09	1985-10-29	Takeda Chem Ind Ltd	インタ−ロイキン−２組成物
US4650674A (en) *	1984-07-05	1987-03-17	Genentech, Inc.	Synergistic cytotoxic composition
US5034225A (en) *	1985-12-17	1991-07-23	Genentech Inc.	Stabilized human tissue plasminogen activator compositions
JPH0645551B2 (ja) *	1986-01-07	1994-06-15	塩野義製薬株式会社	インタ−ロイキン−２組成物
US4894226A (en)	1986-11-14	1990-01-16	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4931543A (en)	1987-05-11	1990-06-05	Cetus Corporation	Process for recovering microbially produced interleukin-2
ES2044941T5 (es) *	1987-08-21	1999-02-16	Mallinckrodt Group Inc	Estabilizador de hormonas promotoras del crecimiento.
US4883661A (en)	1987-10-09	1989-11-28	Daly John M	Use of arginine as an lymphokine synergist
US5078997A (en) *	1988-07-13	1992-01-07	Cetus Corporation	Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5272135A (en)	1991-03-01	1993-12-21	Chiron Ophthalmics, Inc.	Method for the stabilization of methionine-containing polypeptides
DE4111393A1 (de) *	1991-04-09	1992-10-15	Behringwerke Ag	Stabilisierte faktor viii-praeparationen
FR2684878B1 (fr)	1991-12-12	1994-02-11	Roussel Uclaf	Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
IL107887A (en) *	1992-12-08	2003-07-06	Ambi Inc	Stabilized lanthionine containing bacteriocin compositions
US5358708A (en)	1993-01-29	1994-10-25	Schering Corporation	Stabilization of protein formulations
US5580856A (en) *	1994-07-15	1996-12-03	Prestrelski; Steven J.	Formulation of a reconstituted protein, and method and kit for the production thereof
JP2000510813A (ja)	1995-02-06	2000-08-22	ジェネテイックス・インスティテュート・インコーポレイテッド	Ｉｌ−１２用処方
US5888968A (en) *	1995-06-07	1999-03-30	Chiron Corporation	TFPI formulation
EP1602667B1 (en)	1995-06-07	2007-04-04	Novartis Vaccines and Diagnostics, Inc.	Aqueous formulation comprising TFPI and solubilizing agents
CN102416176A (zh) *	1995-07-27	2012-04-18	基因技术股份有限公司	稳定等渗的冻干蛋白质制剂
JP2001501619A (ja) *	1996-10-04	2001-02-06	アムジェンインコーポレーテッド	ｍｐｌリガンドを含有する医薬組成物
US6262233B1 (en) *	1997-01-31	2001-07-17	Human Genome Sciences, Inc.	Tissue factor pathway inhibitor-3
ES2288018T3 (es)	1998-04-03	2007-12-16	Novartis Vaccines And Diagnostics, Inc.	Formulaciones inyectables de igf que contienen succinato como tampon.
CN1245216C (zh)	1999-10-04	2006-03-15	希龙公司	稳定化的含多肽的液体药物组合物
DE60115422T2 (de) *	2000-05-10	2006-08-17	Novo Nordisk Health Care Ag	PHARMAZEUTISCHE ZUSAMMENSETZUNG ENTHALTEND EINEN FAKTOR VIIa UND EINEN TFPI-INHIBITOR
EP2116265B1 (en) *	2000-10-12	2020-12-23	Genentech, Inc.	Reduced-viscosity concentrated protein formulations
PT1353694E (pt) *	2001-01-26	2008-03-12	Schering Corp	Combinações de ezetimiba com aspirina para o tratamento de doenças vasculares

2000
- 2000-10-03 CN CNB008163286A patent/CN1245216C/zh not_active Expired - Fee Related
- 2000-10-03 PL PL370852A patent/PL211886B1/pl not_active IP Right Cessation
- 2000-10-03 CA CA002386228A patent/CA2386228A1/en not_active Abandoned
- 2000-10-03 EP EP04021066A patent/EP1491208B1/en not_active Expired - Lifetime
- 2000-10-03 CZ CZ2004-1041A patent/CZ305123B6/cs not_active IP Right Cessation
- 2000-10-03 HU HU0800692A patent/HU0800692D0/hu unknown
- 2000-10-03 DE DE60044213T patent/DE60044213D1/de not_active Expired - Lifetime
- 2000-10-03 AU AU78475/00A patent/AU783306B2/en not_active Ceased
- 2000-10-03 BR BR0014486-0A patent/BR0014486A/pt not_active Application Discontinuation
- 2000-10-03 AT AT00968584T patent/ATE345810T1/de not_active IP Right Cessation
- 2000-10-03 IL IL14900800A patent/IL149008A0/xx unknown
- 2000-10-03 AT AT04021066T patent/ATE464062T1/de not_active IP Right Cessation
- 2000-10-03 CN CNB2004100858470A patent/CN100389821C/zh not_active Expired - Lifetime
- 2000-10-03 WO PCT/US2000/027156 patent/WO2001024814A1/en active Application Filing
- 2000-10-03 JP JP2001527813A patent/JP2003510368A/ja active Pending
- 2000-10-03 PT PT04021066T patent/PT1491208E/pt unknown
- 2000-10-03 EP EP00968584A patent/EP1220682B1/en not_active Expired - Lifetime
- 2000-10-03 PL PL00354987A patent/PL354987A1/xx not_active Application Discontinuation
- 2000-10-03 CZ CZ20021186A patent/CZ20021186A3/cs unknown
- 2000-10-03 CA CA2477857A patent/CA2477857C/en not_active Expired - Lifetime
- 2000-10-03 DE DE60031999T patent/DE60031999T2/de not_active Expired - Lifetime
- 2000-10-03 NZ NZ529856A patent/NZ529856A/en unknown
- 2000-10-03 NZ NZ535205A patent/NZ535205A/en not_active IP Right Cessation
- 2000-10-03 US US09/677,643 patent/US6525102B1/en not_active Expired - Fee Related
- 2000-10-03 ES ES00968584T patent/ES2276698T3/es not_active Expired - Lifetime
- 2000-10-03 HU HU0401975A patent/HU227347B1/hu unknown
- 2000-10-03 HU HU0203133A patent/HUP0203133A3/hu unknown
- 2000-10-03 BR BRPI0017437A patent/BRPI0017437B8/pt not_active IP Right Cessation
2002
- 2002-04-03 NO NO20021567A patent/NO20021567L/no not_active Application Discontinuation
- 2002-04-04 IL IL149008A patent/IL149008A/en active IP Right Grant
- 2002-11-18 US US10/299,039 patent/US7030086B2/en not_active Expired - Fee Related
2004
- 2004-10-15 NO NO20044406A patent/NO20044406L/no not_active Application Discontinuation
- 2004-10-29 JP JP2004317319A patent/JP2005068158A/ja active Pending
2005
- 2005-12-05 US US11/293,322 patent/US7807142B2/en not_active Expired - Fee Related
- 2005-12-05 US US11/293,379 patent/US20060093598A1/en not_active Abandoned
2006
- 2006-01-13 AU AU2006200141A patent/AU2006200141B2/en not_active Ceased
2007
- 2007-12-18 IL IL188230A patent/IL188230A0/en unknown

Also Published As

Publication number	Publication date
CA2386228A1 (en)	2001-04-12
US20060093598A1 (en)	2006-05-04
CN1402640A (zh)	2003-03-12
BR0014486A (pt)	2002-09-17
IL149008A (en)	2009-11-18
EP1491208B1 (en)	2010-04-14
AU7847500A (en)	2001-05-10
CZ20021186A3 (cs)	2002-11-13
HU0800692D0 (en)	2009-01-28
NO20021567D0 (no)	2002-04-03
PL211886B1 (pl)	2012-07-31
NZ529856A (en)	2005-09-30
NZ535205A (en)	2006-01-27
DE60031999D1 (de)	2007-01-04
HUP0203133A3 (en)	2005-07-28
ATE464062T1 (de)	2010-04-15
BR0017437A (pt)	2002-09-17
EP1220682B1 (en)	2006-11-22
NO20044406L (no)	2002-05-22
PL354987A1 (en)	2004-03-22
CN100389821C (zh)	2008-05-28
BRPI0017437B1 (pt)	2016-06-07
DE60044213D1 (de)	2010-05-27
CN1245216C (zh)	2006-03-15
US20060093576A1 (en)	2006-05-04
CA2477857A1 (en)	2001-04-12
HU0401975D0 (en)	2004-11-29
AU2006200141B2 (en)	2009-07-02
JP2005068158A (ja)	2005-03-17
US20030180253A1 (en)	2003-09-25
US7030086B2 (en)	2006-04-18
HUP0401975A3 (en)	2010-01-28
DE60031999T2 (de)	2007-06-06
HU227347B1 (en)	2011-04-28
CZ305123B6 (cs)	2015-05-13
JP2003510368A (ja)	2003-03-18
ES2276698T3 (es)	2007-07-01
IL149008A0 (en)	2002-11-10
US6525102B1 (en)	2003-02-25
HUP0203133A2 (hu)	2002-12-28
US7807142B2 (en)	2010-10-05
AU2006200141A1 (en)	2006-02-09
EP1491208A1 (en)	2004-12-29
EP1220682A1 (en)	2002-07-10
ATE345810T1 (de)	2006-12-15
BRPI0017437B8 (pt)	2021-05-25
CA2477857C (en)	2012-04-10
WO2001024814A1 (en)	2001-04-12
PT1491208E (pt)	2010-05-12
IL188230A0 (en)	2008-03-20
AU783306B2 (en)	2005-10-13
CN1636592A (zh)	2005-07-13

Legal Events

Date	Code	Title	Description
2010-05-31	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20021567D0 (no)	2002-04-03	Stabiliserte flytende polypeptidinneholdende farmasöytiske sammensetninger
MXPA03011041A (es)	2004-03-19	Composiciones farmaceuticas que contienen orlistat y acidos grasos y/o sales de los mismos.
EE04911B1 (et)	2007-10-15	Ühend ja farmatseutiline kompositsioon proteaasi inhibiitoritena, nende kasutamine ning meetod selle ühendi valmistamiseks
EA200200938A1 (ru)	2003-02-27	Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
HUP0204136A2 (hu)	2003-03-28	Eljárások az interleukin-2 tüdőbe juttatására
EA200001125A1 (ru)	2001-04-23	Гелеобразные фармацевтические композиции
PT1589949E (pt)	2008-11-06	Composições liofilizadas estabilizadas compreendendo inibidor da coagulação por factores tecidulares ou variante de inibidor da coagulação por factores tecidulares
GEP20115206B (en)	2011-04-26	Novel piperidine carboxylic acid amide derivatives
RU2013150659A (ru)	2015-05-20	Пероральное введение кальцитонина
CA2480226A1 (en)	2003-10-02	Stable pharmaceutical composition containing factor viii
DK1588707T3 (da)	2009-03-09	Stabilt fast medicinsk præparat til oral administration af ramosetron
EA200401298A1 (ru)	2005-02-24	Жидкие фармацевтические композиции, содержащие низкую дозу энтекавира, и их применение
NO20020176L (no)	2002-01-14	Sykliske peptidderivater som inhibitorer for intergrin <alfa>v<beta>6
BR0211060A (pt)	2004-07-20	Formulação lìquida compreendendo cetuximab e um éster de ácido graxo de polioxietileno sorbitano
FR2846883B1 (fr)	2004-12-24	Composition cosmetique comprenant, comme ingredient actif, au moins un peptide et utilisation de ce peptide
BR9908479A (pt)	2000-12-05	Composições farmacêuticas que contêm o inibidor de fosfolipase [[3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil_-1h-indol- 4-il]óxil] acetato de sódio
WO2003026582A3 (en)	2003-10-16	Method of preparing phenoxy alkanoic, alkenoic, and alkynoic acids and salts thereof via a dicarboxylate intermediate
DE69918098D1 (de)	2004-07-22	Neue suesstoffzusammensetzungen
IL117816A0 (en)	1996-08-04	N-subsituted azaheterocyclic compounds their preparation and pharmaceutical compositions containing them
DE69208171D1 (de)	1996-03-21	Gallensäuren enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
KR930012023A (ko)	1993-07-20	환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
KR900014429A (ko)	1990-10-23	폴리펩티드 유도체 및 칼슘 대사 향진제
JPH04270227A (ja)	1992-09-25	ヒト組織プラスミノーゲン活性化因子含有組成物
IT1307866B1 (it)	2001-11-19	Composizioni farmaceutiche contenenti inibitori dell'ormone dellacrescita o loro frammenti biologicamente attivi per il trattamento
JPH08225459A (ja)	1996-09-03	カルシトニンの注射用製剤